Enanta Pharmaceuticals (NASDAQ:ENTA) released its earnings results on Tuesday. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.27, Briefing.com reports. The firm had revenue of $44.40 million during the quarter, compared to analyst estimates of $46.98 million. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The business’s revenue was down 22.5% on a year-over-year basis. During the same quarter last year, the business earned $0.97 EPS.
ENTA traded up $1.56 on Wednesday, reaching $72.39. 316,049 shares of the company traded hands, compared to its average volume of 223,163. Enanta Pharmaceuticals has a one year low of $64.08 and a one year high of $106.80. The firm has a fifty day moving average price of $81.97. The firm has a market capitalization of $1.37 billion, a P/E ratio of 20.80 and a beta of 0.98.
Several equities research analysts have recently issued reports on ENTA shares. Wolfe Research started coverage on shares of Enanta Pharmaceuticals in a report on Friday, May 24th. They issued an “outperform” rating and a $117.00 target price for the company. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 17th. Berenberg Bank upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a report on Tuesday, April 23rd. Finally, BidaskClub lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $109.00.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its holdings in Enanta Pharmaceuticals by 8.1% during the 2nd quarter. Janus Henderson Group PLC now owns 944,787 shares of the biotechnology company’s stock valued at $79,721,000 after buying an additional 70,390 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at about $224,000. JPMorgan Chase & Co. lifted its holdings in Enanta Pharmaceuticals by 90.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 109,185 shares of the biotechnology company’s stock valued at $9,154,000 after buying an additional 52,004 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Enanta Pharmaceuticals by 6.1% during the 2nd quarter. Wells Fargo & Company MN now owns 28,826 shares of the biotechnology company’s stock valued at $2,432,000 after buying an additional 1,668 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its holdings in Enanta Pharmaceuticals by 7.1% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 9,359 shares of the biotechnology company’s stock valued at $790,000 after buying an additional 620 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Recommended Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.